Evaxion (NASDAQ: EVAX) sets March 5 call on 2025 results

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, will provide a business update and report its full year 2025 financial results on March 5, 2026 before the opening of the Nasdaq Capital Market.

Executive management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Participants can register in advance to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website after the event.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On March 2, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to announce business update and full year 2025 financial results on March 5, 2026". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion to announce business update and full year 2025 financial results on March 5, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: March 2, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What did Evaxion A/S (EVAX) announce in this Form 6-K?

Evaxion A/S announced it will provide a business update and report full year 2025 financial results on March 5, 2026. The update will be accompanied by a management-hosted conference call and webcast that includes a presentation and Q&A session for participants.

When will Evaxion (EVAX) release its full year 2025 financial results?

Evaxion will release its full year 2025 financial results on Thursday, March 5, 2026, before the opening of the Nasdaq Capital Market. A business update will be provided at the same time, followed by a conference call and webcast later that day.

What time is Evaxion’s 2025 results conference call and webcast?

The conference call and webcast will take place on March 5, 2026, at 14:30 CET / 08:30 EST. Executive Management will present the business update and financial results and then take questions from participants during the live event.

How can investors join Evaxion’s March 5, 2026 earnings call?

Investors can join the conference call by registering in advance via the provided link to receive dial-in numbers and a unique PIN code. They can also access a webcast through a separate link, with a recording available on Evaxion’s website afterward.

What does Evaxion A/S (EVAX) focus on as a business?

Evaxion A/S is a clinical-stage TechBio company built on its proprietary AI-Immunology™ platform. It uses artificial intelligence to decode the human immune system and develop vaccine candidates for cancer and infectious diseases, including both personalized and off-the-shelf approaches.

Where can I find the recording of Evaxion’s 2025 results presentation?

A recording of the webcast will be available on Evaxion’s website shortly after the March 5, 2026 event. This allows investors and other stakeholders to review the business update and full year 2025 financial results presentation at their convenience.

Who is the investor relations contact for Evaxion A/S (EVAX)?

The investor relations contact is Mads Kronborg, Vice President, Investor Relations & Communication at Evaxion A/S. The filing provides his telephone number and email address, enabling investors and analysts to request additional information or clarification about the company’s activities.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.1 KB